Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Wegovy under the microscope: Real-World weight loss study begins

NCT ID NCT07055607

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 4 times

Summary

This two-year study will follow 1,250 people with obesity who are starting Wegovy (semaglutide) as part of their regular medical care. Researchers will track changes in weight, waist size, and quality of life to see how the drug performs outside of clinical trials. The goal is to understand the real-world impact of Wegovy when prescribed by doctors in everyday practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide (Wegovy)
What this could lead to
If successful, this study could show how well Wegovy works for weight loss in everyday medical practice, not just in controlled trials.
What could go wrong
This is an observational study, not a controlled experiment, so results may be influenced by factors like patient selection or adherence. It does not test a new treatment or prove long-term safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,250 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be treated with Wegovy according to the local labels in Spain, Switzerland and the United Kingdom (UK).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Signed consent obtained before any study-related activities (study-related activities are any pro-cedure related to recording of data according to the protocol). * Are eligible for Wegovy and are due to initiate treatment for the first time within the study period; the decision to initiate treatment with commercially available Wegovy has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study. * Male or female, age above or equal to 18 years at time of signing informed consent. * Have at least one reported weight measurement documented at baseline or within 28 days prior to baseline. * Participants must be able to complete the electronic patient reported outcome (ePRO) questionnaires on a compatible electronic device with internet access. * Fulfil the respective reimbursement criteria in the visit prior to / at baseline in Switzerland and United Kingdom (UK). Exclusion criteria: * Previous participation in this study. Participation is defined as having given informed consent in this study. * Presence of a documented refusal or unwillingness to participate in research. * Previous treatment with other obesity management pharmacotherapy or any glucagon like pep-tide-1 (GLP- 1) receptor agonist up to 90 days prior to baseline in Switzerland and UK. * Previous treatment with other obesity management pharmacotherapy or any GLP- 1 receptor agonist up to 30 days prior to baseline in Spain. * Pregnant or women of childbearing potential and not using a highly effective contraceptive method. * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation with the study requirements. * Individuals who have reported plans to move out in the next 12 months to an area not serviced by their current site. * Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) in Spain and UK. * Participant has had a prior serious allergic reaction to semaglutide or any of the ingredients in Wegovy. * Have had Saxenda reimbursed by basic mandatory health insurance for a cumulative period of more than 12 months prior to baseline in Switzerland. * Documented history of diabetes mellitus type 1 and type 2 in Spain. * Presence of diabetic complications and/or at risk of hypoglycaemia (with a documented history of frequent hypoglycaemia) in Spain.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    30 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Barnsley Hospital

    Barnsley, S75 2EP, United Kingdom

  • CAP Sants

    Barcelona, 08028, Spain

  • CAP Sarrià

    Barcelona, 08017, Spain

  • Centre médical de l'obésité et du diabète

    Neuchâtel, 2000, Switzerland

  • Centro de Salud Cartagena Casco Antiguo

    Cartagena, 30201, Spain

  • Centro de Salud La Cuesta

    La Cuesta (Santa Cruz de Tenerife), 38320, Spain

  • Clinica Moncucco

    Lugano, 6900, Switzerland

  • Clínica de Endocrinología y Nutrición Dr. Bellido

    Ferrol, 15401, Spain

  • Ginegetafe S.L.

    Getafe (Madrid), 28901, Spain

  • Hospital Quirónsalud Málaga

    Málaga, 29004, Spain

  • Hospital Son Espases

    Palma de Mallorca, 07120, Spain

  • Hospital Univ. Central de Asturias

    Oviedo, 33011, Spain

  • Hospital Univ. Virgen de la Arrixaca

    El Palmar (Murcia), 30120, Spain

  • Hospital Univ. de Gran Canaria Doctor Negrín

    Las Palmas de Gran Canaria, 35010, Spain

  • Hospital Universitario Sanitas Virgen del Mar

    Madrid, 28016, Spain

  • Hospital Vall d'Hebron

    Barcelona, 08035, Spain

  • Hospital Vithas Sevilla

    Castilleja de la Cuesta, 41950, Spain

  • Hospiten Roca_Ginecología

    San Bartolomé de Tirajana (Las Palmas), 35100, Spain

  • Hull Royal Infirmary

    Hull, HU3 2JZ, United Kingdom

  • Hôpitaux Universitaires de Genève HUG

    Geneva, 1211, Switzerland

  • Kantonsspital Olten

    Olten, 4600, Switzerland

  • Luton and Dunstable University Hospital

    Luton, LU4 0DZ, United Kingdom

  • Luzerner Kantonsspital

    Lucerne, 6004, Switzerland

  • Praxis Dr. Schäfer, Bern

    Bern, 3013, Switzerland

  • Praxis Prof. Dr. med. G. Rudofsky

    Olten, 4600, Switzerland

  • Sandwell Health Campus

    West Bromwich, West Midlands, B71 4HJ, United Kingdom

  • St George's Hospital

    Tooting, SW17 0RE, United Kingdom

  • St Thomas' Hospital - Diabetes

    London, SE1 7EH, United Kingdom

  • Stoffwechselzentrum St. Gallen

    Sankt Gallen, 9016, Switzerland

  • Universitätsspital Zürich

    Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.